Spero Therapeutics   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Cambridge MA United States (2013)

Organization Overview

First Clinical Trial
2016
NCT03022175
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Spero Therapeutics | Spero Therapeutics Inc | Spero Therapeutics, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 3)

Infections (Phase 3)

Mycobacterium avium-intracellulare Infection (Phase 2)

Mycobacterium Infections (Phase 2)

Pyelonephritis (Phase 3)

Renal Insufficiency (Phase 1)

Urinary Tract Infections (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 17
  • # of Trial APIs: 21